Podcast
MSL Talk: Tom Caravela
Compliance 101-Most common issues and MSL-related gray areas
Summary
In this episode, Jessica McLin and Melody Davis explore the intricacies of compliance and communication in medical affairs. Jessica shares her journey into entrepreneurship and discusses her work with Versant Learning Solutions. The conversation covers FDA standards, ethical collaboration with sales reps, and the importance of understanding company SOPs. They delve into strategies for navigating compliance gray areas and the role of training, especially in smaller companies. The episode also highlights the significance of professional development through conferences and the importance of leadership in enforcing compliance. Finally, they address key compliance rules and best practices for MSLs, including the Sunshine Act.
Today’s guests are Jessica McLin and Melody Davis of Versant Learning. We discuss MSL Compliance 101 and the most common issues and MSL-related gray areas.
In this episode we discuss:
- Jessica and Melody intro
- What Versant Learning does
- Compliance and what people need to know
- The most common gray areas to look out for
- Where can an MSL find compliance information outside their current organization
- The role of MSL Leadership in communicating compliance standards and how much of the effort lies on the MSL
- The most important for the MSLs to keep in mind
compliance in medical affairs, MSL compliance, FDA standards, ethical collaboration, professional development conferences
Related Topics
You May Also Like
MSL Talk: Tom Caravela
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret